Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...
NJBIZ

Cellares, BMS announce $380M cell therapy manufacturing agreement

Bristol Myers Squibb and Cellares announced Monday a worldwide capacity reservation and supply agreement for the manufacturing of CAR T cell therapies. The transaction is valued at up to $380 million ...

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to ...
BioWorld

BMS-986458, a CRBN-mediated LDD targeting BCL6 for B-cell NHL treatment

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...